Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies.

Anwar M Hashem, Rowa Y Alhabbab, Abdullah Algaissi, Mohamed A Alfaleh, Sharif Hala, Turki S Abujamel, M-Zaki ElAssouli, Afrah A AL-Somali, Fadwa S Alofi, Asim A Khogeer, Almohanad A Alkayyal, Ahmad Bakur Mahmoud, Naif A M Almontashiri, Arnab Pain

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally. Although several rapid commercial serological assays have been developed, little is known about their performance and accuracy in detecting SARS-CoV-2-specific antibodies in COVID-19 patient samples. Here, we have evaluated the performance of seven commercially available rapid lateral flow immunoassays (LFIA) obtained from different manufacturers, and compared them to in-house developed and validated ELISA assays for the detection of SARS-CoV-2-specific IgM and IgG antibodies in RT-PCR-confirmed COVID-19 patients. While all evaluated LFIA assays showed high specificity, our data showed a significant variation in sensitivity of these assays, which ranged from 0% to 54% for samples collected early during infection (3-7 days post symptoms onset) and from 54% to 88% for samples collected at later time points during infection (8-27 days post symptoms onset). Therefore, we recommend prior evaluation and validation of these assays before being routinely used to detect IgM and IgG in COVID-19 patients. Moreover, our findings suggest the use of LFIA assays in combination with other standard methods, and not as an alternative.
Original languageEnglish (US)
Pages (from-to)1067
JournalPathogens (Basel, Switzerland)
Volume9
Issue number12
DOIs
StatePublished - Dec 23 2020

Bibliographical note

KAUST Repository Item: Exported on 2020-12-28
Acknowledged KAUST grant number(s): BAS/1/1020/01/01
Acknowledgements: The authors extend their appreciation to the deputyship for Research and Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number (436) to AMH. AP and SH are supported by a faculty baseline funding by KAUST to AP (BAS/1/1020/01/01) and the R3T initiative of KAUST.

Fingerprint

Dive into the research topics of 'Performance of Commercially Available Rapid Serological Assays for the Detection of SARS-CoV-2 Antibodies.'. Together they form a unique fingerprint.

Cite this